Norrin mediates opposing effects on tumor progression of glioblastoma stem cells

Area of Science:

• Neuro-oncology
• Cancer Stem Cell Biology
• Molecular Signaling Pathways

Background:

• Glioblastoma (GBM) is an aggressive brain cancer driven by glioblastoma stem cells (GSCs).
• Understanding GSC regulatory mechanisms is crucial for developing effective GBM therapies.
• The Wnt/β-catenin signaling pathway plays a role in cancer development.

Purpose of the Study:

• To investigate the dual role of Norrin, a Wnt/β-catenin activator, in glioblastoma stem cell proliferation.
• To determine the influence of the transcription factor ASCL1 on Norrin's effect on GSCs.
• To evaluate the therapeutic potential of modulating Norrin in glioblastoma models.

Main Methods:

• Analysis of Norrin's effect on GSCs with varying ASCL1 expression levels.
• In vivo studies involving modulation of Norrin expression in glioblastoma xenografts.
• Assessment of tumor growth, GSC proliferation, and mouse survival rates.

Main Results:

• Norrin inhibited GSC growth in cells with low ASCL1 expression via β-catenin signaling.
• Norrin promoted GSC growth in cells with high ASCL1 expression.
• Norrin also activates the Notch pathway, contributing to enhanced tumor growth.
• Modulating Norrin based on ASCL1 levels significantly reduced tumor growth in vivo and improved mouse survival.

Conclusions:

• Norrin exhibits opposing effects on glioblastoma tumor growth, dependent on ASCL1 expression levels in GSCs.
• Norrin's pro-tumorigenic effect is partly mediated through Notch pathway activation.
• Targeting Norrin, considering ASCL1 expression, presents a promising therapeutic strategy for glioblastoma.